Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells

Toxicology Mechanisms and Methods

Volumn 23, Issue 2, 2013, Pages 120-126

  Pourkhalili, Nazila ^a   Ghahremani, Mohammad Hossein ^a   Farsandaj, Narges ^a   Tavajohi, Shohreh ^a   Majdzadeh, Maryam ^a   Parsa, Maliheh ^a   Lavasani, Nasir Jafar ^a   Ostad, Seyed Nasser ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cannabinoids; Hepatocellular carcinoma (HCC); HepG2 cell; Invasion

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACEA; CANNABINOID; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR AGONIST; CB65; GELATINASE A; GELATINASE B; MATRIGEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH CURVE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ARACHIDONIC ACIDS; CANNABINOIDS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84873882332     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.730559     Document Type: Article

References (39)

1. Bifulco M, Laezza C, Pisanti S, Gazzerro P. 2006. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148: 123-135.
2. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V. 2001. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 2745-2747.
3. Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G, Malumbres M, Guzmán M. 2006. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 20: 2633-2635.
4. Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C. 2006. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66: 6615-6621.
5. Carracedo A, Gironella M, Lorente M, Garcia S, Guzmán M, Velasco G, Iovanna JL. 2006a. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66: 6748-6755.
6. Carracedo A, Lorente M, Egia A, Blázquez C, García S, Giroux V, Malicet C, Villuendas R, Gironella M, González-Feria L, Piris MA, Iovanna JL, Guzmán M, Velasco G. 2006b. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9: 301-312.
7. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M. 2003. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111: 43-50.
8. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ. 2009. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 39: 177-186.
9. Chen P, Hu S, Yao J, Moore SA, Spector AA, Fang X. 2005. Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 69: 28-35.
10. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
11. Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. 2000. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313-319.
12. Ghahremani MH, Forget C, Albert PR. 2000. Distinct roles for Galpha(i)2 and Gbetagamma in signaling to DNA synthesis and Galpha(i)3 in cellular transformation by dopamine D2S receptor activation in BALB/c 3T3 cells. Mol Cell Biol 20: 1497-1506.
13. Gialeli C, Theocharis AD, Karamanos NK. 2011. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27.
14. Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, Vento R, Tesoriere G. 2009. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie 91: 457-465.
15. Gustafsson K, Christensson B, Sander B, Flygare J. 2006. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol 70: 1612-1620.
16. Guzmán M. 2003. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745-755.
17. Liang JA, Wu SL, Lo HY, Hsiang CY, Ho TY. 2009. Vanillin inhibits matrix metalloproteinase-9 expression through down-regulation of nuclear factor-kappaB signaling pathway in human hepatocellular carcinoma cells. Mol Pharmacol 75: 151-157.
18. Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V. 2006. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387.
19. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M. 2002. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627-634.
20. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 16: 55-63.
21. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. 1975. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55: 597-602.
22. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. 2000. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149.
23. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I. 2009. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940-950.
24. Pellerito O, Calvaruso G, Portanova P, De Blasio A, Santulli A, Vento R, Tesoriere G, Giuliano M. 2010. The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol Pharmacol 77: 854-863.
25. Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK. 2009. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 8: 3117-3129.
26. Repesh LA. 1989. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9: 192-208.
27. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular Cloning: A Laboratory manual. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press.
28. Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. 2001. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61: 5784-5789.
29. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. 2008. Cannabinoids for cancer treatment: progress and promise. Cancer Res 68: 339-342.
30. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. 2006. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G(1) cell cycle arrest. J Biol Chem 281: 39480-39491.
31. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. 2005. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 1635-1641.
32. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M, Rosenbaum J. 2007. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 46: 69-76.
33. Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X, Lu CX. 2010. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep 23: 1593-1600.
34. Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. 2011. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18: 1099-1111.
35. Velasco G, Carracedo A, Blázquez C, Lorente M, Aguado T, Haro A, Sánchez C, Galve-Roperh I, Guzmán M. 2007. Cannabinoids and gliomas. Mol Neurobiol 36: 60-67.
36. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA. 2009. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 278: 145-155.
37. Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, Fan W, Li Q, Wang Q, Zhong D, Miao X. 2006. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171: 31-38.
38. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, Ogata H, Yano H, Kojiro M, Ueno T, Yoshimura A, Sata M. 2006. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25: 6056-6066.
39. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, Xu J, Qian F, Chen Z. 2006. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 5: 808-814.